RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer.

Yudai YamamotoShu ShimadaYoshimitsu AkiyamaShu TsukiharaRaizo SugimotoAyano KabashimaMasanori TokunagaYusuke KinugasaYutaka KawakamiShinji Tanaka

Published in: Journal of gastroenterology (2023)

We clarified that RTP4 could be silenced by histone H3K9 methylation as the early event of ICB resistance. RTP4 expression could be a promising biomarker for predicting ICB response, and the combination of epigenetic drugs and immune checkpoint inhibitors might exhibit synergistic effects on dMMR/MSI-H CRC.

Keyphrases

dna methylation
poor prognosis
gene expression
genome wide
binding protein
cancer therapy
drug induced